These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9235591)

  • 1. [Changes of isoniazid concentrations in guinea pig blood and organs after various routes of drug administration].
    Kaminskaia GO; Firsova VA; Gubkina MF; Efimova LN
    Probl Tuberk; 1997; (2):45-7. PubMed ID: 9235591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs.
    Pandey R; Sharma S; Khuller GK
    Indian J Exp Biol; 2004 Jun; 42(6):562-6. PubMed ID: 15260105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Morphological reactions in the subcutaneous fat after lymphotropic administration of isoniazid: experimental study].
    Gedymin LE; Firsova VA; Gubkina MF
    Probl Tuberk; 1997; (2):51-4. PubMed ID: 9235595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
    Sharma A; Sharma S; Khuller GK
    J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 8. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis.
    Thee S; Detjen AA; Wahn U; Magdorf K
    Scand J Infect Dis; 2010 Apr; 42(4):294-8. PubMed ID: 20100111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
    Gangadharam PR; Geeta N; Hsu YY; Wise DL
    Int J Tuberc Lung Dis; 1999 Jun; 3(6):515-20. PubMed ID: 10383065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
    Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
    J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.
    McIlleron H; Willemse M; Werely CJ; Hussey GD; Schaaf HS; Smith PJ; Donald PR
    Clin Infect Dis; 2009 Jun; 48(11):1547-53. PubMed ID: 19392636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
    Qurrat-ul-Ain ; Sharma S; Khuller GK; Garg SK
    J Antimicrob Chemother; 2003 Apr; 51(4):931-8. PubMed ID: 12654730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Concentration of isoniazid-H3 in the blood and tissues of experimental animals].
    Cherednichenko LP; Klebanova AA
    Probl Tuberk; 1970; 48(9):69-72. PubMed ID: 5518277
    [No Abstract]   [Full Text] [Related]  

  • 15. The type of isoniazid acetylation in tuberculosis patients treated at National Tuberculosis and Lung Diseases Research Institute.
    Augustynowicz-Kopeć E; Zwolska Z
    Acta Pol Pharm; 2002; 59(6):443-7. PubMed ID: 12669768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of plasma levels of isoniazid for dose adjustment in the hemodialysis patients.
    El Kabbaj D; Aatif M; Moussa LA; Khassouani CE; Oualim Z
    Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):666-7. PubMed ID: 19587514
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Apr; 53(4):635-40. PubMed ID: 14998985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana).
    Maslow JN; Mikota SK; Zhu M; Isaza R; Peddie LR; Dunker F; Peddie J; Riddle H; Peloquin CA
    J Vet Pharmacol Ther; 2005 Feb; 28(1):21-7. PubMed ID: 15720511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.